Nile Therapeutics, Inc. to Present at Upcoming BIO CEO & Investor Conference
The presentation will be webcast live and can be accessed by visiting theInvestor Relations section at www.nilethera.com. The webcast will be archivedfor ninety days. Additional information regarding the BIO Investor Forum canbe accessed at http://ceo.bio.org.
About Nile Therapeutics
Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company thatdevelops innovative products for the treatment of cardiovascular disease andother areas of unmet medical need. Nile is initially focusing its efforts ondeveloping its lead compound, CD-NP, a novel chimeric peptide in Phase Istudies for the treatment of acute decompensated heart failure, and 2NTX-99, asmall molecule, pre-clinical, anti-atherothrombotic agent with nitric oxidedonating properties. A key component of the Company's strategy is to acquirethe global rights to additional compounds to expand its portfolio. Moreinformation on Nile can be found at www.nilethera.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaningof the Private Securities Litigation Reform Act of 1995 that involvesubstantial risks and uncertainties. All statements, other than statements ofhistorical facts, included in this press release regarding our strategy,future operations, outlook, milestones, the success of Nile's productdevelopment, future financial position, future financial results, plans andobjectives of management are forward-looking statements. We may not actuallyachieve these plans, intentions or expectations and Nile cautions investorsnot to place undue reliance on our forward-looking statements. Actual resultsor events could differ materially from the plans, intentions and expectationsdisclosed in the forward-looking statements we make. Various important factorsthat could cause actual results or events to differ materially from theforward-looking statements that we make are described in greater detail in thereports we file with Securities and Exchange Commission, including the "RiskFactors" section of our Prospectus filed pursuant to Rule 424(b)(3) of theSecurities Act of 1933, as amended, with the Securities and ExchangeCommission on November 15, 2007. Nile is providing this information as of thedate of this press release and does not undertake any obligation to update anyforward-looking statements as a result of new information, future events orotherwise.Contact: Daron Evans Chief Financial Officer Nile Therapeutics, Inc. 510-281-7700 firstname.lastname@example.org
SOURCE Nile Therapeutics, Inc.
You May Also Like